Method Development Insights

Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table

Method development is the first real moment of truth in a bioanalytical project. It sets the trajectory for everything that follows, from validation to sample analysis to final reporting.

And yet, one of the most common challenges we see is not technical. It is alignment.

Strong method development does not start in the lab. It starts with what the sponsor brings into the conversation.

Why This Matters 

A well-developed method is not just about sensitivity or selectivity. It is about fitness for purpose.

If the foundation is unclear, teams end up iterating, reworking, and losing time. In early development programs, that time matters.

The difference between a smooth program and a reactive one often comes down to the quality of inputs at the start.

What Sponsors Should Provide Upfront 

1. Clear Study Objectives

What decisions will this data support? This sounds simple, but it drives everything:

• Required sensitivity (LLOQ)
• Dynamic range
• Turnaround expectations
• Regulatory expectations

Without this, method development becomes guesswork.

2. Molecule Understanding

Basic characterization is critical:

• Structure and class (small molecule, peptide, ADC, etc.)
• Solubility
• Known metabolites or expected biotransformations
• Stability profile (if known)

Any previous observations helps the lab anticipate challenges early.

3. Matrix and Species Strategy

Where will this method be applied?

• Preclinical species vs. clinical
• Plasma, serum, tissue, or microsamples
• Special populations or conditions

Matrix drives complexity. Tissue and microsampling require very different approaches than standard plasma work.

4. Expected Concentration Ranges

Even rough estimates are valuable:

• C_max expectations
• Anticipated PK profile
• Dose levels

This informs assay range and avoids rework when real samples arrive.

5. Reference Materials and Standards

Availability and quality matter:

• Certificate of Analysis
  • Purity
  • Storage conditions
• API standards
• Internal standards
• Metabolite standards (if applicable)

Delays here can stall development entirely.

6. Regulatory Context

Is this:

• Exploratory
• GLP toxicology
• Clinical (GCP-aligned)

The level of rigor and documentation changes based on intended use.

7. Timeline and Priorities

Be explicit:

• Key milestones
• Critical path studies
• Flexibility vs. fixed deadlines

This helps labs allocate resources appropriately and avoid surprises.

Where Things Break Down 

Most issues we see are not capability gaps. They are communication gaps.

• Assumptions about expected sample concentrations
• Late changes in matrix or species
• Misalignment on regulatory expectations

These lead to avoidable delays and rework.

Best Practice: Treat Method Development as a Partnership 

The most successful programs share a common approach:

• Early, direct communication with scientific teams
• Transparent discussion of risks and unknowns
• Willingness to align on “fit-for-purpose” vs. “perfect”

Method development is not a transactional step. It is a strategic one.

Final Thought 

If you want speed, quality, and reliability downstream, invest the time upfront. The best bioanalytical methods are not just developed. They are built on clarity.

Looking for more information on method development?

Download the “Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table” Infographic
An easy-to-use reference that highlights seven key elements

Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.